Canaccord Genuity Starts Pacific Biosciences of California (PACB) at Buy, Sees 75%+ Upside
Tweet Send to a Friend
Canaccord Genuity analyst Kyle Mikson initiates coverage on Pacific Biosciences of California (NASDAQ: PACB) with a Buy rating and a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE